Detalles de la búsqueda
1.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
N Engl J Med
; 386(4): 316-326, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35081280
2.
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Ann Rheum Dis
; 82(3): 331-343, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36600185
3.
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Ann Rheum Dis
; 82(1): 119-129, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36137735
4.
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Ann Rheum Dis
; 80(8): 1004-1013, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33906853
5.
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
N Engl J Med
; 377(16): 1525-1536, 2017 10 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29045207
6.
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
N Engl J Med
; 377(16): 1537-1550, 2017 10 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29045212
7.
Population pharmacokinetics of tofacitinib in patients with psoriatic arthritisâ©.
Int J Clin Pharmacol Ther
; 57(9): 464-473, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31319908
8.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Lancet
; 390(10093): 457-468, 2017 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-28629665
9.
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Ann Rheum Dis
; 82(4): 575-577, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36720582
10.
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Ann Rheum Dis
; 76(8): 1340-1347, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28130206
11.
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Clin Exp Rheumatol
; 34(2): 318-28, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26966791
12.
Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation and Quality Consortium Perspective on Use Cases and Best Practices.
Clin Pharmacol Ther
; 115(4): 658-672, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37716910
13.
Advancing the utilization of real-world data and real-world evidence in clinical pharmacology and translational research-Proceedings from the ASCPT 2023 preconference workshop.
Clin Transl Sci
; 17(4): e13785, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38572980
14.
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
Arthritis Rheumatol
; 2024 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38481002
15.
Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Clin Pharmacol Ther
; 114(4): 751-767, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37393555
16.
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.
Ther Adv Musculoskelet Dis
; 15: 1759720X231201047, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37942277
17.
Estimating transformations for repeated measures modeling of continuous bounded outcome data.
Stat Med
; 30(9): 935-49, 2011 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-21472758
18.
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift).
RMD Open
; 7(2)2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34103405
19.
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.
Lancet Rheumatol
; 3(4): e270-e283, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279411
20.
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Lancet Rheumatol
; 3(1): e28-e39, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38273637